XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, FiscalAI reports.
XTL Biopharmaceuticals Stock Down 1.6%
Shares of XTLB opened at $1.51 on Friday. XTL Biopharmaceuticals has a twelve month low of $1.39 and a twelve month high of $5.64. The firm’s 50 day moving average price is $1.98 and its 200 day moving average price is $2.56.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of XTL Biopharmaceuticals in a report on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, XTL Biopharmaceuticals currently has a consensus rating of “Sell”.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. is an Israel-based company listed on Nasdaq that has focused on developing and commercializing biopharmaceutical products. Its business strategy has also included acquiring and developing pharmaceutical and medical-device businesses. Historically, the company pursued drug candidates for autoimmune diseases. Its research included hCDR1, an investigational peptide studied for systemic lupus erythematosus. These programs reflect its earlier development work and should not necessarily be understood as products currently marketed by the company.
Recommended Stories
- Five stocks we like better than XTL Biopharmaceuticals
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
